Saturday, October 3, 2026

USD/EUR Bearish Momentum: 0.94% Down In The Last 10 Sessions

ViaNews Editorial Team

October 11, 2023

USD/EUR Bearish Momentum: 0.94% Down In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.94% for the last 10 sessions. At 08:07 EST on Wednesday, 11 October, USD/EUR (USDEUR) is $0.94.

USD/EUR's yearly highs and lows, it's 6.314% up from its 52-week low and 9.144% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.25%, a positive 0.03%, and a positive 0.31%, respectively.

USD/EUR's highest amplitude of average volatility was 0.25% (last week), 0.29% (last month), and 0.31% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy treading water near 148.60 as investors sniff out US inflation figures. According to FXStreet on Wednesday, 11 October, "The USD/JPY continues to soar high above the 200-day Simple Moving Average (SDMA), which is currently riding up into the 139.00 chart region, with technical support for the pair currently sitting near 147.00 from the 50-day SMA.", "The long-term trend outlook for the USD/JPY is exceedingly bullish, with the Greenback trading well above the median against the Yen. "
  • Usd/jpy technical analysis: demand for buying safe havens - 10 October 2023. According to DailyForex on Tuesday, 10 October, "Accordingly, the USD/JPY currency pair jumped towards the resistance level of 149.23 before settling around the level of 148.70 at the time of writing the analysis. ", "Therefore, USD/JPY is likely to continue rising as buyers target the next major resistance level at 151.96 (October 22 high). "
  • Usd/jpy drops on risk-aversion spurred on middle-east tensions, falling US bond yields. According to FXStreet on Monday, 9 October, "The USD/JPY remains neutral to upward bias, with price action remaining above the Ichimoku Cloud (Kumo). ", "On the other hand and the path of least resistance, the USD/JPY could test the 150.00 figure, but first it needs to conquer 149.00"
  • Usd/jpy price analysis: struggles to capitalize on modest intraday bounce from one-week low. According to FXStreet on Tuesday, 10 October, "A generally positive risk tone is seen undermining the safe-haven Japanese Yen (JPY) and turning out to be a key factor lending some support to the USD/JPY pair. ", "From a technical perspective, the USD/JPY pair now seems to have found acceptance below the 100-period Simple Moving Average (SMA) on the 4-hour chart. "
  • Usd/jpy oscillates at around 148.60 amidst dovish fed remarks, risk-on impulse. According to FXStreet on Tuesday, 10 October, "Nevertheless, the USD/JPY rally was capped by the US Treasury bond yields plunge as the 10-year benchmark note sits at 4.632%, dropping 17 basis points since Monday."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com